Leptocarpin Suppresses Proliferation, Migration, and Invasion of Human Osteosarcoma by Targeting Type-1 Insulin-Like Growth Factor Receptor (IGF-1R)

**Background:** Leptocarpin (LTC) has drawn much attention for suppressing tumor growth or reducing inflammation. However, the effect of LTC on osteosarcoma has rarely been reported. Our object was to determine whether LTC suppresses MG63 cell proliferation, migration, and invasion, and whether type-1 insulin-like growth factor receptor (IGF-1R) is one of the targets in LTC suppressing osteosarcoma.

**Material/Methods:** Cytotoxicity of LTC was performed by use of a cell-counting kit-8 (CCK-8). RNA interference (RNAi) or pEABE-bleo IGF-1R plasmid were used for silencing or overexpressing IGF-1R, Western blot (WB) analysis was used for IGF-1R expression, CCK-8 for proliferation, and transwell assay for migration and invasion.

**Results:** LTC (23.533 μM) treatment for 48 h was taken as the 50% inhibiting concentration (IC50), which significantly (\(P<0.05\)) suppressed MG63 cells proliferation, migration, and invasion. LTC (IC50) obviously inhibited IGF-1R expression in MG63 cells, with similar effect to small interfering RNA (siRNA), while pEABE-bleo IGF-1R transfection overexpressed IGF-1R. siRNA silencing IGF-1R suppressed MG63 cells proliferation, migration, and invasion, while pEABE-bleo IGF-1R transfection was significantly (\(P<0.05\)) promoted. With or without siRNA or pEABE-bleo IGF-1R transfection, LTC (IC50) suppressed MG63 cells proliferation, migration, and invasion. The effect of LTC (IC50) combined with siRNA on suppressing MG63 cells proliferation, migration, and invasion was more obvious, while the effect of LTC (IC50) combined with pEABE-bleo IGF-1R transfection was less significant (\(P<0.05\)).

**Conclusions:** LTC suppressed osteosarcoma proliferation, migration, and invasion by inhibiting IGF-1R expression. IGF-1R is one of the targets in LTC suppressing osteosarcoma.

**MeSH Keywords:** Cell Migration Inhibition • Cell Proliferation • Osteosarcoma

**Full-text PDF:** https://www.medscimonit.com/abstract/index/idArt/903427
Background

Bone is a dynamic tissue with a rigid and mineralized extracellular matrix. It undergoes constant remodeling, which is determined by the effect of osteoclast activity [1]. During this process, old and damaged bone and osteoblasts are resorbed, while new mineralized extracellular matrix is synthesized [2,3]. Bone remodeling plays an important role in maintaining structure throughout life, with an intimate interaction between osteoclastic and osteoblastic activities [3]. The imbalance between bone resorption and synthesis leads to loss of bone integrity and function, as well as bone metabolic disorders [4].

Osteosarcoma, involving the formation of malignant osteoid or woven bone, is one of the most common tumors clinically, which frequently affects children and young adults [5]. Osteosarcoma is related to high rates of bone destruction with great biological virulence [6]. However, further attention should be on the metastases and invasion of osteoclastic cells, even with osteosarcoma, clinically. According to a previous report [6], tumor-associated osteoclasts were found in 63% of patients by histological and pathological detections, as well as in 75% by mRNA analysis. This indicates that there is a close relationship between osteoclastic activity and osteosarcoma aggressiveness. In our research, MG63 cells were used to investigate the effect of LTC on migration, invasion, and proliferation.

In the clinical treatment of neoplasia, chemotherapeutic drugs, which may be natural products or chemical derivatives, are used increasingly and widely [7]. Recently, the research on new products with potential biological activity has been focused on medicinal plants. Asteraceae, which produces many bioactive compounds such as polyacetylenes, diterpenes, and sesquiterpene lactones [8], expresses various clinical activities, including anti-tumor, anti-ulcer, anti-inflammatory, neurotoxic, and cardiotonic activities [9,10], as well as the ability to influence critical biological processes such as cell signaling, cell proliferation, apoptosis, and mitochondrial metabolism [11]. Leptocarpin (LTC) is the one of the major components of Leptocarpha rivularis, which belongs to the Asteraceae family and was widely used as a folk remedy [12–14]. In our study, LTC was used as an anti-tumor drug to treat MG63 cells.

At the genetic level, previous research [15] has shown that many genetic and epigenetic agents are involved in tumor pathogenesis and progression. According to Liu et al. [16], PMP22 (peripheral myelin protein 22) was found to be overexpressed in osteosarcoma. The in vivo experiments proved the relationship between PMP22 and the proliferation, migration, invasion, and colony formation of osteosarcoma cells. In addition, Actein was found to inhibit osteosarcoma proliferation and migration by Chen et al. [17]. Burguera et al. [18] studied the role of leptin in human osteosarcoma cells, and they found that leptin promoted osteosarcoma cell proliferation, which was related to the activation of PI(3)K and MAPK pathways. All of these results suggest that many molecules play important roles in tumor proliferation and migration.

IGF-1R is a member of the tyrosine protein kinase receptor family. It participates in the establishment of a malignant cell phenotype [19], cell metastasis [20], protection from apoptosis [21], and enhancement of cell proliferation [22]. According to Hirano et al. [23], high level of IGF-1R expression, as the critical prognostic factor, was correlated to tumor progression in human endometrial carcinoma. Pavelic et al. [24] also found that endometrial cancer cells synthesized and secreted IGF-I and IGF-II, integrating with IGF-1R and inducing tumor proliferation. Although IGF-1R is highly overexpressed in most malignant tissues, where it functions as an anti-apoptotic agent by enhancing cell survival, whether IGF-1R could be used as a molecular target in suppressing osteosarcoma growth has been unknown.

Here, we used RNAi to silence IGF-1R gene expression to investigate the role of IGF-1R in LTC suppressing MG63 cell proliferation, migration, and invasion.

Material and Methods

MG63 cell

MG63 cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured in Dulbecco’s modified Eagle’s medium (DMEM, Thermo Fisher Scientific Inc., Shanghai, China) containing 10% fetal bovine serum (FBS, Gibco, Thermo, Shanghai, China), amphotericin (2.5 μg/mL, Sigma-Aldrich Inc., Shanghai, China), penicillin (100 U/mL, Sigma-Aldrich), and streptomycin (100 μg/mL, Sigma-Aldrich) under conditions of 5% CO₂, 37°C, and saturated humidity. When 90% confluent, the cells were digested with 0.25% trypsin-EDTA (Thermo) and subcultured.

LTC preparation

LTC was extracted from Leptocarpha rivularis according to previous methods [25] and sent to the Scistd Testing Institute (Qingdao, China) for structural identification by spectroscopic techniques (¹H and ¹³C NMR, IR, MS). LTC was dissolved in dimethylsulfoxide (DMSO, Sigma-Aldrich), with primary concentration adjusting as 1 mg/mL and stored at −20°C. Before use, LTC (1 mg/mL) was diluted with medium as given concentrations from 1.0 to 25.0 μM.

LTC cytotoxicity screening in MG63 cells by CCK-8

MG63 cells were digested and the concentration was adjusted to 3000 cells in 200 μL medium per well in a 96-well plate.
After culturing for 24 h, MG63 cells were treated with LTC (1.0, 2.5, 5.0, 7.5, 10.0, 12.5, 15.0, 20.0, 22.5 and 25.0 μM). The negative control (NC) group was the MG63 cells treated with 0.1% DMSO. All the cells were incubated at 37°C, with 5% CO₂ and saturated humidity, for 24, 48, and 72 h. After treatments, 10 μl of CCK-8 buffer was added to each well. The cells were detected at 450 nm by an enzyme mark instrument (Synergy HTX multi-mode reader, BioTek Instruments, Co., Ltd., USA) after 20 min. The data obtained are shown as percentages of living cells versus the control, expressed as mean ± standard deviation (SD).

**Silencing IGF-1R**

siRNA targeting IGF-1R (5′-GCC GAT GTG TGA AGC-3′) was synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China). IGF-1R siRNA was used to transfect MG63 cells with Lipofectamine® 3000 reagent (Thermo) according to the specifications. MG63 cells were cultured subsequently for 72 h. Then, LTC was used to treat MG63 cells and were compared to NC (0.1% DMSO).

**Overexpressing IGF-1R**

pEABE-bleo IGF-1R plasmid was obtained from Addgene (Beijing Zhongyuan, Ltd. China). MG63 cells were transfected with pEABE-bleo IGF-1R plasmid by Lipofectamine® 3000 reagent for 48 h and then treated with LTC and compared to NC (0.1% DMSO).

**Detection on MG63 cell migration and invasion**

For detection of MG63 invasion, 5 μl Matrigel (Becton, Dickinson and Company, BD, USA) was spread in the upper chamber of a transwell 24-well plate (BD). Following treatment with LTC for 48 h or 72 h, MG63 cells were cultured with DMEM without FBS or antibiotics for 6 h, and then digested as density of 1×10⁴ cells/mL with DMEM without FBS. We added 0.5 mL of the cell suspension to each upper chamber of the 24-well plate, while 0.5 mL DMEM containing 10% FBS was added to the lower chamber. The upper chamber was placed in the appropriate lower chamber. After 24 h, the Matrigel and the MG63 cells in the upper chambers were cleaned carefully and thoroughly. The upper and lower chambers were washed once with 1×PBS and the cells were fixed with 4% parafomaldehyde (Solarbio Science and Technology Co., Ltd. Beijing China) for 20 min. MG63 cells in the lower surface of the upper chambers were stained with 0.25% crystal violet (Macklin Inc. Shanghai, China), which was dissolved in 20% methanol, for 20–45 min. The samples were washed twice with PBS and the membrane of the chamber was sealed with cover balsam (Leica Biosystems, Germany). The membrane was wetted with PBS and observed under a microscope (Nikon, Japan). Five fields (20×) were selected randomly and the number of MG63 cells was counted, with the average number and the comparisons analysis.

For detection MG63 cell migration, the protocol was the same as for invasion, but without Matrigel.

**Detections of IGF-1R expression**

Total proteins in MG63 cells were extracted with loading buffer (2×) and the concentrations were determined with a BCA protein assay kit (Beyotime Biotechnology Company, Shanghai, China) according to the specifications. The proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with a 10% separating gel and 5% stacking gel. Then, the protein was transferred to polyvinylidene fluoride (PVDF) membranes (Merck Millipore Corporation, Darmstadt, Germany), and the membranes were blocked with 5% non-fat milk and 2% bovine serum albumin (BSA, Gen-View Scientific Inc., USA) in PBS-T (PBS containing 0.25% Tween-20, Macklin) at 25°C for 1.5 h. The membranes were incubated with rabbit anti-IGF-1R primary antibodies (1: 4000, Proteintech Group Inc., Wuhan, China) and mouse anti-β-actin (1: 10 000, Proteintech), as internal control, at 4°C overnight. The next day, the membranes were incubated with goat anti-rabbit and goat anti-mouse secondary antibodies (1: 3000, Jackson ImmunoResearch Laboratories, Inc. USA) at 25°C for 2 h, and then analyzed with electrochemiluminescence (ECL, Millipore, MA, USA).

**Statistical analysis**

All the data were analyzed using SPSS 19.0 software. The data are shown as mean ± standard deviation (X±SD). Cell proliferation is shown as optical density (OD) value. Cell migration and invasion are shown as cell amount. One-way ANOVA was used for comparisons among all treatments. IC₅₀ was analyzed by probit regression. Least significant difference (LSD) was used for multiple comparisons when there was homogeneity of variance, while Dunnett’s T3 test was used with heterogeneity of variance. P<0.05 was considered to indicate a significant difference.

**Results**

**LTC suppressing MG63 cells proliferation**

The cytotoxicity of LTC is shown in Table 1 and Figure 1A. There was no significant difference in MG63 proliferation with different LTC concentrations treatment for 24 h. Treating for 48 h, the proliferation of MG63 cells treated with LTC (10.0–25 μM) were both significantly (P<0.05) lower than the NC. The proliferation of MG63 cells treated with LTC (7.5–25 μM) for 72 h
were significantly ($P<0.05$) lower than the NC. The IC50 was 23.533 μM LTC (95% CI=22.269~25.088) treated for 48 h or 16.548 μM LTC (95% CI=15.017~18.345) treated for 72 h. Therefore, two IC50 values were obtained, 23.533 μM LTC treated for 48 h and 16.548 μM LTC treated for 72 h. We chose 23.533 μM LTC treated for 48 h as the final IC50 in the following treatments.

**LTC inhibits IGF-1R expression in MG63 cells**

As shown in Figure 1B, siRNA or 23.533 μM LTC treated for 48 h decreased IGF-1R expression in MG63 cells, while pEA-BE-bleo IGF-1R clearly increased IGF-1R expression, indicating the successfully overexpression or silencing of IGF-1R. After overexpression of IGF-1R, 23.533 μM LTC treatment for 48 h obviously decreased IGF-1R in MG63 cells compared to 0.1% DMSO treatment. On the other hand, after silencing IGF-1R, 23.533 μM LTC treatment for 48 h further decreased IGF-1R in MG63 cells compared to 0.1% DMSO or LTC treatment alone.

**LTC suppresses MG63 cells migration and invasion**

The results of migration and invasion of MG63 cells are shown in Table 2, Figure 1C, and Figure 1D. There were significant ($P<0.05$) differences in migration (Figure 1Ca, 1Cb) and invasion (Figure 1Da, 1Db) of MG63 cells treated with 23.533 μM LTC for 48 h.

**LTC suppresses MG63 cell proliferation**

As shown in Table 3, Figures 2A and 2B, we compared the proliferation rate of MG63 cells with different treatments. MG63 cells proliferation rate was promoted after overexpressing IGF-1R, but suppressed after silencing IGF-1R, which indicates that overexpressed IGF-1R promotes MG63 cells proliferation. LTC 23.533 μM treatment for 48 h obviously suppressed MG63 cells proliferation compared to NC. Additionally, siRNA silencing IGF-1R combined with 23.533 μM LTC treatment for 48 h further suppressed MG63 cells proliferation compared to siRNA or LTC treatment alone.

**Table 1. Effect of 0.1% DMSO or LTC (1.0~25μM) on MG63 cells proliferation in 24 h, 48 h and 72h (X±SDs).**

| Time | NC (0.1% DMSO) | LTC (1.0 μM) | LTC (2.5 μM) | LTC (5.0 μM) | LTC (7.5 μM) | LTC (10.0 μM) | LTC (12.5 μM) | LTC (15.0 μM) | LTC (17.5 μM) | LTC (20.0 μM) | LTC (22.5 μM) | LTC (25.0 μM) |
|------|----------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| 24 h | 0.176±0.034    | 0.179±0.008 | 0.168±0.016 | 0.159±0.019 | 0.162±0.025 | 0.156±0.018 | 0.155±0.037 | 0.150±0.054 | 0.145±0.008 | 0.149±0.017 | 0.140±0.018 | 0.137±0.021 |
| 48 h | 0.510±0.079    | 0.506±0.075 | 0.504±0.042 | 0.505±0.086 | 0.492±0.071 | 0.451±0.027 | 0.427±0.016 | 0.387±0.060 | 0.355±0.200 | 0.301±0.016 | 0.285±0.074 | 0.265±0.043 |
| 72 h | 0.986±0.047    | 0.924±0.068 | 0.910±0.094 | 0.782±0.087 | 0.706±0.071 | 0.685±0.069 | 0.595±0.043 | 0.510±0.036 | 0.428±0.029 | 0.353±0.053 | 0.332±0.078 | 0.306±0.071 |

DMSO – dimethylsulfoxide; LTC – Leptocarpin; NC – negative control group; $^1$ comparing to the NC (72h), $P<0.05$; $^2$ comparing to the NC (48h), $P<0.05$.
Osteosarcoma, a malignant bone tumor, affects many children and young adults worldwide. To find new anti-tumor drugs and targets for the treatment of osteosarcoma, we chose MG63 cells as the subject and used LTC as the anti-tumor drug. By silencing IGF-1R with RNAi, we found that IGF-1R was one of the targets in LTC’s suppression of MG63 cell proliferation, invasion, and migration.

LTC is a sesquiterpene lactone, a major component of the Asteraceae family [25]. According to Martinez et al. [12], LTC exhibits high cytotoxicity on human liver adenocarcinoma (SK-Hep-1) and HeLa cells. Therefore, LTC has anti-cancer and anti-tumor effects [26–28]. However, there is less study focusing on the effect of LTC on osteosarcoma. In our investigations, we studied the cytotoxicity of LTC on MG63 cells, and we found that LTC (10.0~25 μM) treatment for 48 h and LTC (7.5~25 μM) 5.0~25 μM treatment for 48 h and LTC (7.5~25 μM)

**Discussion**

Osteosarcoma, a malignant bone tumor, affects many children and young adults worldwide. To find new anti-tumor drugs and targets for the treatment of osteosarcoma, we chose MG63 cells as the subject and used LTC as the anti-tumor drug. By silencing IGF-1R with RNAi, we found that IGF-1R was one of the targets in LTC’s suppression of MG63 cell proliferation, invasion, and migration.

LTC is a sesquiterpene lactone, a major component of the Asteraceae family [25]. According to Martinez et al. [12], LTC exhibits high cytotoxicity on human liver adenocarcinoma (SK-Hep-1) and HeLa cells. Therefore, LTC has anti-cancer and anti-tumor effects [26–28]. However, there is less study focusing on the effect of LTC on osteosarcoma. In our investigations, we studied the cytotoxicity of LTC on MG63 cells, and we found that LTC (10.0~25 μM) treatment for 48 h and LTC (7.5~25 μM)
Table 3. Effect of LTC and/or siRNA targeting IGF-1R on MG63 cells proliferation (X±SDs).

| Type | OD value       | Proliferation rate (%) |
|------|----------------|------------------------|
| NC   | 0.534±0.041    | 100.00                 |
| pEABE-bleo IGF-1R | 0.874±0.033    | 164.67^2               |
| siRNA| 0.305±0.024    | 57.12^2,4              |
| LTC  | 0.270±0.034    | 50.56^2,3              |
| pEABE-bleo IGF-1R+NC | 0.836±0.027    | 157.55^1,3,4,5,6       |
| siRNA+NC | 0.434±0.025    | 81.27^1,2,4,5,6,7      |
| siRNA+LTC | 0.265±0.043    | 49.63^1,2,5,6,7        |

Type-1 insulin-like growth factor receptor; LTC – Leptocarpin; NC – negative control group; DMSO – dimethylsulfoxide; ^1 comparing to NC (0.1% DMSO, 72 h), P<0.05; ^2 comparing to pEABE-bleo IGF-1R, P<0.05; ^3 comparing to siRNA, P<0.05; ^4 LTC (23.533 μM, 48 h), P<0.05; ^5 comparing to pEABE-bleo IGF-1R+NC (0.1% DMSO, 48 h), P<0.05; ^6 comparing to pEABE-bleo IGF-1R +LTC (23.533 μM, 48 h), P<0.05; ^7 comparing to siRNA+NC (0.1% DMSO, 48 h), P<0.05.
Figure 2. Effect of LTC on MG63 cell proliferation, migration, and invasion with different treatments. (A) Effect of LTC on MG63 cell proliferation. (B) Effect of LTC on MG63 cell proliferation rate (1) compared to NC (0.1% DMSO, 72 h), P<0.05; (2) compared to pEABE-bleo IGF-1R, P<0.05; (3) compared to siRNA, P<0.05; (4) LTC (23.533 μM, 48 h), P<0.05; (5) compared to pEABE-bleo IGF-1R+NC (0.1% DMSO, 48 h), P<0.05; (6) compared to pEABE-bleo IGF-1R+LTC (23.533 μM, 48 h), P<0.05; (7) compared to siRNA+NC (0.1% DMSO, 48 h), P<0.05. (C) Effect of LTC on MG63 cell migration and invasion. (D) Effect of LTC on MG63 cell migration and invasion rates (1) compared to NC (0.1% DMSO, 48 h) of migration, P<0.05; (2) compared to pEABE-bleo IGF-1R of migration, P<0.05; (3) compared to siRNA of migration, P<0.05; (4) compared to LTC (23.533 μM, 48 h) of migration, P<0.05; (5) compared to pEABE-bleo IGF-1R+ NC (0.1% DMSO, 48 h) of migration, P<0.05; (6) compared to pEABE-bleo IGF-1R+ LTC (23.533 μM, 48 h) of migration, P<0.05; (7) compared to siRNA+NC (0.1% DMSO, 48 h) of migration, P<0.05; (8) compared to LTC (23.533 μM, 48 h) of invasion, P<0.05; (9) compared to pEABE-bleo IGF-1R of invasion, P<0.05; (10) compared to siRNA of invasion, P<0.05; (11) compared to LTC (23.533 μM, 48 h) of invasion, P<0.05; (12) compared to pEABE-bleo IGF-1R+ NC (0.1% DMSO, 48 h) of invasion, P<0.05; (13) compared to pEABE-bleo IGF-1R+ LTC (23.533 μM, 48 h) of invasion, P<0.05; (14) compared to siRNA+NC (0.1% DMSO, 48 h) of invasion, P<0.05. (E) Effect of LTC on MG63 cell migration. (F) Effect of LTC on MG63 cell invasion.
Leptocarpin suppresses osteosarcoma by IGF-1R

Zheng S. et al.: Leptocarpin suppresses osteosarcoma by IGF-1R © Med Sci Monit, 2017; 23: 4132-4140

Table 4. Effect of LTC and/or siRNA targeting IGF-1R on MG63 cells migration and invasion (X±SDs).

|                        | Migration   | Migration rate (%) | Invasion    | Invasion rate (%) |
|------------------------|-------------|--------------------|-------------|-------------------|
| NC (0.1% DMSO, 48 h)   | 96.17±8.44  | 100                | 87.56±9.10  | 100               |
| pEABE-bleo IGF-1R      | 122.94±12.50| 127.84             | 106.38±15.12| 121.49            |
| siRNA                  | 66.33±10.05 | 68.97±1.2          | 52.56±10.28 | 60.03             |
| LTC (23.533 μM, 48 h)  | 60.24±7.95  | 62.64±1.2          | 51.89±7.03  | 59.26             |
| pEABE-bleo IGF-1R+ NC  | 119.48±8.35 | 124.24±1.4         | 103.16±10.75| 117.82            |
| pEABE-bleo IGF-1R+ LTC | 82.15±9.84  | 85.42±1.4          | 76.09±6.51  | 86.90             |
| siRNA+NC (0.1% DMSO, 48 h) | 60.17±9.61 | 62.57±1.5          | 51.29±7.52  | 58.58             |
| siRNA+LTC (23.533 μM, 48 h) | 33.80±6.25 | 35.15±1.2          | 28.06±4.73  | 32.05             |

Type-1 insulin-like growth factor receptor; LTC – Leptocarpin; NC – negative control group; DMSO, dimethylsulfoxide; 1 comparing to NC (0.1% DMSO, 48 h) of migration, P<0.05; 2 comparing to pEABE-bleo IGF-1R of migration, P<0.05; 3 comparing to siRNA of migration, P<0.05; 4 comparing to LTC (23.533 μM, 48 h) of migration, P<0.05; 5 comparing to pEABE-bleo IGF-1R+ NC (0.1% DMSO, 48 h) of migration, P<0.05; 6 comparing to pEABE-bleo IGF-1R+ LTC (23.533 μM, 48 h) of migration, P<0.05; 7 comparing to siRNA+NC (0.1% DMSO, 48 h) of migration, P<0.05; 8 comparing to NC (0.1% DMSO, 48 h) of invasion, P<0.05; 9 comparing to siRNA+LTC (23.533 μM, 48 h) of invasion, P<0.05; 10 comparing to siRNA of invasion, P<0.05; 11 comparing to pEABE-bleo IGF-1R of invasion, P<0.05; 12 comparing to LTC (23.533 μM, 48 h) of invasion, P<0.05; 13 comparing to pEABE-bleo IGF-1R+ NC (0.1% DMSO, 48 h) of invasion, P<0.05; 14 comparing to pEABE-bleo IGF-1R+ LTC (23.533 μM, 48 h) of invasion, P<0.05.

Treatment for 72 h both obviously suppressed MG63 cell proliferation. These results indicate that a high concentration of LTC had obvious effects on MG63 cell proliferation, in agreement with previous reports. By analysis the IC50, we chose 23.533 μM LTC treatment for 48 h in the following experiments. By detecting migration and invasion, we found that 23.533 μM LTC treatment for 48 h obviously suppressed MG63 cell migration and invasion, supporting the previous investigations mentioned above.

IGF-1R, a tetrameric transmembrane receptor tyrosine kinase, is expressed widely in normal human tissues. Increasing evidence suggests that IGF-1R is associated with progression of human tumors [29]. Jasminke et al. [30] found that IGF-1R was overexpressed in endometrial carcinoma. According to Martinez et al. [14], LTC had no effect on DNA or RNA synthesis but produced marked effects on the protein biosynthesis in cancerous cell lines, which showed the biological activity of LTC, as an anti-neoplastic agent of natural origin.

To confirm the promotion of overexpressed IGF-1R on tumor cell proliferation, we referred to previous studies [16,17] and detected the IGF-1R expression in MG63 cells. We found that LTC treatment obviously inhibited IGF-1R expression in MG63 cells, similar to results of siRNA silencing IGF-1R. Even after overexpressing IGF-1R, LTC still decreased IGF-1R expression. By detecting proliferation, migration, and invasion, we found that MG63 cell proliferation, migration, and invasion were obviously suppressed by LTC treatment, even in the MG63 cells with overexpressed IGF-1R. Additionally, siRNA also suppressed MG63 cell proliferation, migration, and invasion, but the effect of siRNA combined with LTC was more powerful than LTC treatment alone. These results suggest that IGF-1R has important roles in LTC’s suppression of MG63 cells proliferation, migration, and invasion.

Claudia et al. [31] also found that LTC decreased cell viability of cancer cell lines via inducing an apoptotic process and inhibiting the NF-kB signaling pathway. LTC is also an effective inhibitor of NF-kB, which is involved in cell growth, including apoptosis and proliferation, and even migration and invasion. Therefore, other targets that LTC acts on might be critical proteins in the NF-kB signaling pathway. Unfortunately, we did not detect the role of IGF-1R in the NF-kB signaling pathway in LTC treatment of MG63 cells. Animal experiments are needed to confirm this hypothesis in vivo.

Conclusions

We found that LTC suppressed osteosarcoma proliferation, migration, and invasion. IGF-1R is one of the targets in LTC’s suppression of osteosarcoma, which provides clinical treatments for osteosarcoma with a new drug and molecular target. Further investigations are needed to demonstrate the role of IGF-1R in LTC’s suppression of osteosarcoma, and animal experiments are also needed.
Statement

All the authors declare no conflict of interest in this work. Each author contributed equally in this work. We received no financial support for this work. All the expenditure was supplied by Huizhou First Hospital.

References:

1. Hadjidakis DJ, Androulakis II: Bone Remodeling. Ann NY Acad Sci, 2006; 1092(1): 385–96
2. Ralcz LC: Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest, 2005; 115(12): 3318–25
3. Zaidi M: Skeletal remodeling in health and disease. Nat Med, 2007; 13(7): 791–801
4. Clezardin P, Teti A: Bone metastasis: Pathogenesis and therapeutic implications. Clin Exp Metastasis, 2007; 24(8): 599–608
5. San-Julian M, Diaz-de-Rada P, Noain E, Sierrasesumaga L: Bone metastasis from osteosarcoma. Int Orthop, 2003; 27(27): 117–20
6. Amyot S, Longhi A, Salerno M et al: Increased osteoclast activity is associated with aggressiveness of osteosarcoma. Int J Oncol, 2008; 33(6): 1233–38
7. Newman DJ, Cragg GM: Natural products as sources of new drugs over the last 30 years from 1981 to 2010. J Nat Prod, 2012; 75(3): 311–35
8. Robles M, Aregullin M, West J, Rodriguez E: Recent studies on the zoopharmacognosy, pharmacology and neurotoxicology of sesquiterpene lactones. Planta Med, 1995; 61(3): 199–203
9. Modzelewska A, Sur S, Kumar SK, Khan SR: Sesquiterpenes: Natural products that decrease cancer growth. Curr Med Chem Anticancer Agents, 2005; 5(5): 477–99
10. Zhang S, Won YK, Ong CN, Shen HM: Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr Med Chem Anticancer Agents, 2005; 5(3): 239–49
11. Wu C, Chen F, Rushing JW et al: Antiproliferative activities of parthenolide and golden feverfew extract against three human cancer cell lines. J Med Food, 2006; 9(1): 55–61
12. Martínez R, Kesternich V, Gutierrez E et al: Conformational analysis and biological activity of L. rivularis. J Nat Prod, 1995; 61(2): 188–99
13. Martínez R, Kesternich V, Carrasco H, Fernandez S: Structure, conformation and biological activity studies on rivularin, a new heliangolide isolated from Leptocarpia rivularia. Boletin De La Sociedad Chilena De Quimica, 1998; 41(3): 7–12
14. Martínez R, Kesternich V, Carrasco H, Cárcamo J: Synthesis and conformational analysis of Leptocarpia derivatives: Influence of modification of the oxirane ringon Leptocarpia’s cytotoxic activity. Journal of the Chilean Chemical Society, 2006; 51(4): 1010–14
15. Nisha B, Vimala Y, Venham RM: The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control, 2009; 16(1): 8–13
16. Liu S, Chen Z: The functional role of PMP22 gene in the proliferation and invasion of osteosarcoma. Med Sci Monit, 2015; 21: 1976–82
17. Chen Z, Wu J, Guo Q: Actein inhibits cell proliferation and migration in human osteosarcoma. Med Sci Monit, 2016; 22: 1609–16
18. Burguera B, Brunetto A, Garcia-Ocana A et al: Leptin increases proliferation of human osteosarcoma cells through activation of PI(3)-K and MAPK pathways. Med Sci Monit, 2006; 12(11): BR341–49
19. Morrison KB, Tognoz CE, Garnett MI et al: ETv4-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation. Oncogene, 2002; 21(37): 5684–95
20. Samani AA, Chevet E, Fallavollita L et al: Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. Cancer Res, 2004; 64(10): 3380–85
21. Baserga R: The insulin-like growth factor I receptor: A key to tumor growth? Cancer Res, 1995; 55(2): 249–52
22. Casamassima A, Razengurt E: Insulin-like growth factor 1 stimulates tyrosine phosphorylation of p130(Cas), focal adhesion kinase, and paxillin. Role of phosphatidylinositol 3’-kinase and formation of a p130(Cas).Crk complex. J Biol Chem, 1998; 273(40): 26149–56
23. Hirose S, Ito N, Takahashi S, Tamaya T: Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. Eur J Gynaecol Oncol, 2004; 25(2): 187–91
24. Jasminka P, Branko R, Kresimir P: Insulin-like growth factor 2 and its receptors (IGF-1R and IGF-2R) in endometrial adenocarcinoma. Gynecol Oncol, 2007; 105(3): 727–35
25. Rolando Martínez J, Ismael S, Ayamante B et al: Leptocarpin and 17,18-dihydroLeptocarpin, two new heliangolides from Leptocarpia rivularia. Phytochemistry, 1979; 18(9): 1527–28
26. Cho JY, Kim AR, Jung JH et al: Cytotoxic and pro-apoptotic activities of cycrostiparin, a sesquiterpene lactone, on the viability of leukemia cancer cell lines. Eur J Pharmacol, 2004; 492(s 2–3): 85–94
27. Lee KH, Huang ES, Plantadosi C et al: Cytotoxicity of Sesquiterpene Lactones. Cancer Res, 1971; 31(11): 1640–45
28. Taniguchi M, Kataoka T, Suzuki H et al: Costunolide and dehydrocostus lactone as inhibitors of killing function of cytotoxic T lymphocytes. Biosci Biotechnol Biochem, 1995; 59(11): 2064–67
29. Haim W: For debate: the pathophysiological significance of IGF-1 receptor overexpression: new insights. Pediatr Endocrinol Rev, 2009; 7(1): 2–5
30. Pavelić J, Radaković B, Pavelić K: Insulin-like growth factor 2 and its receptors (IGF-1R and IGF-2R) in endometrial adenocarcinoma. Gynecol Oncol, 2007; 105(3): 727–35
31. Bosio C, Tomasoni G, Martínez R et al: Cytotoxic and apoptotic effects of Leptocarpin, a plant-derived sesquiterpene lactone, on human cancer cell lines. Chem Biol Interact, 2015; 242: 415–21

© Med Sci Monit, 2017; 23: 4132-4140

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [EMBASE/Excerpta Medica] [SciVerse Scopus] [Chemical Abstracts/CAS] [Index Copernicus]